Brian Slomovitz, MD, MS, FACOG

Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

Brian Slomovitz, MD, MS, FACOG, discusses the potential use of tisotumab vedotin-tftv in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.

Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.

Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.

Practical perspectives on the optimal use of combination lenvatinib-pembrolizumab in endometrial cancer.

Insight on the combination of lenvatinib and pembrolizumab in endometrial cancer, investigated between the KEYNOTE-146 and KEYNOTE-775 trials.

Brian Slomovitz, MD, MS, FACOG, provides a brief review of endometrial cancer relapse and corresponding therapeutic approaches.

Expert perspectives on the endometrial cancer treatment landscape in light of approved therapies and drug classes.

Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.